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Original Article

Trial of Roflumilast Cream
for Chronic Plaque Psoriasis
Mark G. Lebwohl, M.D., Kim A. Papp, M.D., Ph.D., Linda Stein Gold, M.D.,
Melinda J. Gooderham, M.D., Leon H. Kircik, M.D., Zoe D. Draelos, M.D.,
Steven E. Kempers, M.D., Mathew Zirwas, M.D., Kathleen Smith, M.B.A.,
David W. Osborne, Ph.D., Marie‑Louise Trotman, M.S., Lynn Navale, M.S.,
Charlotte Merritt, M.B.A., David R. Berk, M.D., and Howard Welgus, M.D.,
for the ARQ-151 201 Study Investigators*

A BS T R AC T
BACKGROUND

Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in
the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is
being investigated for the topical treatment of psoriasis.
METHODS

In this phase 2b, double-blind trial, we randomly assigned adults with plaque
psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream,
or vehicle (placebo) cream once daily for 12 weeks. The primary efficacy outcome
was the investigator’s global assessment (IGA) of a status of clear or almost clear
at week 6 (assessed on a 5-point scale of plaque thickening, scaling, and erythema;
a score of 0 indicates clear, 1 almost clear, and 4 severe). Secondary outcomes included an IGA score indicating clear or almost clear plus a 2-grade improvement
in the IGA score for the intertriginous area and the change in the Psoriasis Area
and Severity Index (PASI) score (range, 0 to 72, with higher scores indicating worse
disease). Safety was also assessed.
RESULTS

Among 331 patients who underwent randomization, 109 were assigned to roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle cream. An
IGA score indicating clear or almost clear at week 6 was observed in 28% of the
patients in the roflumilast 0.3% group, in 23% in the roflumilast 0.15% group, and
in 8% in the vehicle group (P<0.001 and P = 0.004 vs. vehicle for roflumilast 0.3%
and 0.15%, respectively). Among the approximately 15% of patients overall who had
baseline intertriginous psoriasis of at least mild severity, an IGA score at week 6
indicating clear or almost clear plus a 2-grade improvement in the intertriginousarea IGA score occurred in 73% of the patients in the roflumilast 0.3% group, 44%
of those in the roflumilast 0.15% group, and 29% of those in the vehicle group. The
mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline
at week 6 was −50.0%, −49.0%, and −17.8%, respectively. Application-site reactions
occurred with similar frequency in the roflumilast groups and the vehicle group.
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CONCLUSIONS

Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks.
Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. (Funded by Arcutis Biotherapeutics; ARQ-151 201 ClinicalTrials.gov
number, NCT03638258.)
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igh-potency topical glucocorticoids and vitamin D derivatives are the
main treatments for psoriasis. Topical
glucocorticoids are effective in the treatment of
psoriasis, but their use is usually limited to no
more than 2 to 8 weeks, and they may be associated with adverse events that resolve slowly, such
as skin atrophy, or that are irreversible with
long-term use, such as striae.1,2 Vitamin D derivatives are less efficacious than topical glucocorticoids and can cause local irritation.3 Topical
calcineurin inhibitors are not approved for the
treatment of psoriasis but have been used offlabel to treat facial and intertriginous psoriasis.4
The frequency of their use decreased when blackbox warnings were added regarding a risk of
cancer. They are not effective on nonfacial, intertriginous sites. Likewise, the retinoid prodrug
topical tazarotene has been used but can be locally irritating.5 Treatment of sensitive areas such
as the face and intertriginous areas with topical
agents requires special consideration because of
the sensitivity of the skin in these areas as well
its thinness — factors that potentially enhance
systemic absorption.
Phosphodiesterase type 4 (PDE-4) is an enzyme that maintains intracellular levels of cyclic
adenosine monophosphate (cAMP)6 and mediates biologic responses to extracellular stimuli
in numerous cell types, including immune cells.7
PDE-4 activity is greater in psoriatic skin than in
healthy skin,8 and inhibition of PDE-4 results in
down-regulation of immune modulators, including tumor necrosis factor α, interferon-γ, interleukin-17, and interleukin-23.9 The oral PDE-4
inhibitor apremilast has been approved for the
treatment of moderate-to-severe plaque psoriasis,10
and crisaborole ointment has been approved for
the treatment of atopic dermatitis11; however, topical PDE-4 inhibitors are currently not approved
for the treatment of psoriasis.
The topical PDE-4 inhibitor roflumilast, a
once-daily cream consisting of roflumilast in a
high-water-content moisturizing cream base vehicle containing the cosmetic solvent ethoxydiglycol (Transcutol), is being investigated for the
treatment of plaque psoriasis. A previous 1-month,
phase 2a trial involving 89 patients showed reductions in severity and size of up to three target
psoriatic plaques and showed that roflumilast had
a safety profile similar to that of the vehicle (placebo) cream.12 In this phase 2b trial, we evaluated
230
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the efficacy and safety of two dose levels of roflumilast cream, administered daily over a period of
12 weeks, for the treatment of plaque psoriasis.

Me thods
Trial Design and Oversight

We conducted this parallel-group, double-blind,
placebo vehicle–controlled trial at 30 sites in the
United States and Canada. The trial enrolled adults
with mild, moderate, or severe chronic plaque psoriasis affecting 2 to 20% of the body-surface area,
excluding the scalp, palms, and soles. Patients
were randomly assigned in a 1:1:1 ratio to receive
roflumilast 0.3% cream, roflumilast 0.15% cream,
or vehicle (placebo) cream, applied once daily to
affected skin areas for 12 weeks.
At week 12, patients could enter an open-label
extension study for up to 12 months. Patients
who did not enter the open-label study had a final
follow-up visit at week 16. Roflumilast cream or
the vehicle cream was applied once daily to all
psoriasis lesions, including those on the face
and in intertriginous areas but not including any
areas on the scalp. The palms and the soles of the
feet were treated but were not counted toward any
measurements of efficacy.
The trial was conducted in accordance with
the principles of the Declaration of Helsinki and
the Good Clinical Practice guidelines of the International Council for Harmonisation. The protocol, available with the full text of this article
at NEJM.org, was approved by the Aspire Institutional Review Board for U.S. sites, by the Western
Institutional Review Board for sites in Canada,
and by local institutional review boards for sites
not covered by these central institutional review
boards. All the patients provided written informed
consent before the initiation of trial-specific procedures.
The first and last authors designed the trial,
with input from the other authors. The sponsor,
Arcutis Biotherapeutics, provided the roflumilast
cream and placebo vehicle cream, compiled the
data, and paid for editorial writing assistance.
Data analysis was performed by the sponsor and
overseen by the authors. The investigators collected
the data and had full editorial control, including
the decision to submit the manuscript for publication. There were confidentiality agreements in
place between the authors and the sponsor. All
the authors vouch for the adherence of the trial
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to the protocol, for the accuracy of the data, and
for the complete reporting of adverse events.
Kits of the active-treatment creams and vehicle cream were labeled with unique, random
numbers and dispensed to the patients. Patients
and assessors of outcomes were unaware of the
trial-group assignments. Randomization was performed according to a computer-generated randomization list.
Eligible patients were 18 years of age or older
and, at the time of their initial trial visit, had had
plaque psoriasis for at least 6 months. Patients
had to have a score indicating a psoriasis status
of at least mild severity (score, ≥2) on a 5-point
investigator’s global assessment (IGA; a 5-point
scale assessing plaque thickening, scaling, and
erythema, ranging from 0 [clear] and 1 [almost
clear] to 4 [severe]). Patients with an IGA score
indicating mild psoriasis (score of 2) were limited to 20% of the total enrollment, patients with
an IGA score indicating severe psoriasis (score of
4) were limited to 15% of the total enrollment,
and all the enrolled patients must have had at
least 2% and no more than 20% involvement of
the body-surface area with plaque psoriasis.
In addition to having an IGA score indicating
a status of at least mild severity (≥2), patients
had to have a score of at least 2 on the modified
Psoriasis Area and Severity Index (PASI; a measurement that combines severity of lesions and
the area affected in one score that ranges from
0 [no disease] to 72 [maximal disease]) at screening. Key exclusion criteria were above-normal exposure to sunlight or tanning beds; diagnosis of
guttate psoriasis (small individual spots of psoriasis), palmoplantar involvement only, or pustular psoriasis; an inability to discontinue treatment
with cytochrome P450 inducers or inhibitors; and
the receipt of oral roflumilast or other PDE-4
inhibitors such as apremilast within the previous
4 weeks.

tion only of intertriginous areas (intertriginousarea IGA).
Other secondary outcomes were the change
in the PASI score14 and the percent of the bodysurface area affected by psoriasis. Secondary outcomes that were patient-reported assessments included the Worst Itch Numeric Rating Scale
(WI-NRS) score, which was assessed on a scale
of 0 (no itch) to 10 (worst itch imaginable) for
the preceding 24 hours15; the Psoriasis Symptom
Diary score, which assessed variables such as
itching, stinging, burning, pain, skin cracking,
scaling, and discoloration (this 16-item scale
evaluates the effect of psoriasis symptoms on
the patient’s life, with each variable scored on a
scale from 0 to 10, with higher scores indicating
greater effect); and the Dermatology Life Quality
Index.16-18 The original protocol included as a
secondary outcome a modified version of the
PASI that we had developed to more precisely
reflect the status of limited disease, in which
involvement of anatomical areas of 1 to 9% of
the body-surface area is recorded as a fraction
instead of being recorded as a “1” (e.g., 0.5 for
5% involvement of the anatomical area). This
measure includes all the elements of the conventional PASI and allows derivation of the PASI
score, which is reported here. Efficacy assessments were conducted at screening, at baseline,
and at weeks 2, 4, 6, 8, and 12 and were considered to be independent outcomes.
Safety was monitored during in-person visits
by means of application-site assessments including investigator-rated skin irritation on a scale of
0 (no evidence of irritation) to 7 (strong reaction
spreading beyond the application site) and patient-rated local symptoms of burning and stinging on a scale of 0 (none) to 3 (severe). Other
safety assessments were laboratory variables,
12-lead electrocardiograms, vital signs, the Patient Health Questionnaire depression scale
(PHQ-8), and the Columbia Suicide Severity Rating Scale (C-SSRS).

Trial Outcomes

Statistical Analysis

The primary efficacy outcome was an IGA status of clear or almost clear (score of 0 or 1)13 at
week 6. For patients with psoriasis of at least
mild severity (IGA score ≥2) in the intertriginous area only at baseline, a separate assessment
as a secondary outcome was conducted with the
use of an analogous IGA scale but with evalua-

Since previous efficacy data regarding the primary outcome in our trial were limited, we did
not determine the sample size on the basis of
the statistical power to calculate significance for
the primary outcome. Efficacy data from the phase
1–2a study12 was considered to broadly support and
justify the conduct of this phase 2b trial, and

Patients
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investigators selected the sample size on the
basis of the desired precision of the resulting estimates. Efficacy analyses were conducted in the
intention-to-treat population (i.e., all the patients
who had undergone randomization).
The primary efficacy outcome of an IGA status
of clear or almost clear (score, 0 or 1) at week 6
was analyzed by logistic regression with trial
group as a factor. The percentage of patients with
an IGA status and intertriginous-area IGA status
of clear or almost clear plus a 2-grade improvement from baseline was determined for each trial
group. Analyses of response included the percentage of patients with an improvement of at least
50%, 75%, or 90% in the PASI score (called
PASI 50, PASI 75, and PASI 90, respectively) and
an improvement of at least 4 points in the WI-NRS
score. The Psoriasis Symptom Diary total score
and the change from baseline in the total score
at weeks 4, 6, 8, and 12 were analyzed. Dichotomized analyses of IGA and PASI scores were
analyzed by logistic regression, and the remaining
secondary efficacy outcomes were analyzed with
the use of analysis of covariance. The results of
the modified PASI, from which the PASI score was
derived, were similar to those for PASI and are
presented in Table S2.
There was no plan for adjustment for multiplicity of secondary outcomes, and these outcomes
are reported as point estimates with multiplicityunadjusted 95% confidence intervals, without P
values, from which no clinical inferences can be
made. Missing efficacy data were imputed with
the use of a mixture of linear interpolation (when
patients had observed values before and after the
missing assessment) and the last-observationcarried-forward approach (when the missing assessment was not followed by a nonmissing value). Analyses were performed primarily with the
use of SAS software, version 9.4 (SAS Institute).
Safety analyses were conducted in the safety
population (i.e., all the patients who received at
least one dose of roflumilast cream or vehicle
cream and had at least one safety assessment).
Adverse events during the intervention period
were coded according to the Medical Dictionary for
Regulatory Activities, version 20.1, with severity
assessed as grade 1 (mild), grade 2 (moderate),
grade 3 (severe), grade 4 (life-threatening consequences), or grade 5 (death related to adverse
event), according to the Common Terminology

232
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Criteria for Adverse Events. The statistical analysis plan is available with the protocol at NEJM.org.

R e sult s
Patients

Between September 21, 2018, and May 29, 2019,
a total of 331 patients (intention-to-treat population) were randomly assigned to receive roflumilast 0.3% cream (109 patients), roflumilast 0.15%
cream (113 patients), or vehicle cream (109 patients) (Fig. 1). (One patient was not included in
the intention-to-treat population because this person underwent randomization in error and did not
receive roflumilast or placebo.) At baseline, the
mean percentage of the body-surface area that
was affected by psoriasis was approximately 6.4%,
and the mean PASI scores ranged from 7.6 to 8.0
(Table 1). Overall, 39 patients (12%) discontinued the trial; more patients completed the trial
in the roflumilast 0.3% group (94%) and the roflumilast 0.15% group (92%) than in the vehicle
group (79%). The safety population comprised
109 patients in the roflumilast 0.3% group, 110 in
the roflumilast 0.15% group, and 107 in the vehicle group.
Efficacy

The primary efficacy outcome of an IGA score
indicating a status of clear or almost clear
(score, 0 or 1) at week 6 was observed in 28% of
the patients in the roflumilast 0.3% group, in
23% of those in the roflumilast 0.15% group,
and in 8% of those in the vehicle group (P<0.001
and P = 0.004 vs. vehicle for roflumilast 0.3% and
0.15%, respectively). An IGA status indicating
clear or almost clear was observed at both weeks
8 and 12 in 38% of the patients in the roflumilast 0.3% group; at these respective time points
in 31% and 32% of the patients in the roflumilast 0.15% group; and at these respective time
points in 12% and 16% of the patients in the
vehicle group. Results regarding the secondary
outcomes, presented with 95% confidence intervals that were not adjusted for multiplicity, are
shown in Table 2 and Table S1 in the Supplementary Appendix; no clinical conclusions can
be drawn from these data because of a lack of
plan for multiple comparisons of secondary outcomes. The percentage of patients with a status
of clear or almost clear plus a 2-grade improve-
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ment from baseline at week 12 was 31% in the
roflumilast 0.3% group, 27% in the roflumilast
0.15% group, and 14% in the vehicle group.
Among the approximately 15% of patients overall who had baseline intertriginous psoriasis of
at least mild severity, an IGA score indicating
clear or almost clear plus a 2-grade improvement
in the intertriginous-area IGA score occurred at
week 6 in 73% of the patients in the roflumilast
0.3% group, in 44% of those in the roflumilast
0.15% group, and in 29% of those in the vehicle
group. By week 12, a total of 14 of 15 patients
(93%) treated with roflumilast 0.3% had an intertriginous-area IGA score of 0 (clear), as compared
with 3 of 17 patients (18%) in the vehicle group.
Reductions in the PASI score in the roflumilast groups as compared with the vehicle group
were in the same direction as the primary outcome from week 2 through week 12; the mean
change from baseline in the PASI score at week 6

was −50.0% in the roflumilast 0.3% group,
−49.0% in the roflumilast 0.15% group, and
−17.8% in the vehicle group. For the PASI 75 response, results with roflumilast 0.3% and 0.15%
as compared with those with vehicle were generally in the same direction as the primary outcome at week 6 through week 12. A total of 31%
of the patients in the roflumilast 3.0% group, as
compared with 13% of those in the vehicle
group, met the criterion for the PASI 75 response
at week 8, and 34% as compared with 16% met
the criterion for the PASI 75 response at week
12. Results for the PASI 90 response and other
secondary outcomes at weeks 4, 6, 8, and 12 are
shown in Table 2 and Table S1. The results of the
modified PASI, from which the PASI score was
derived, were similar to those for PASI and are
presented in Table S2.
Results were generally in the same direction
with regard to the primary outcome among pa-

332 Patients underwent randomization

1 Underwent randomization
in error

109 Were assigned to receive
roflumilast cream, 0.3%

113 Were assigned to receive
roflumilast cream, 0.15%

109 Were assigned to receive vehicle
cream

109 Received roflumilast cream and had
≥1 safety assessment

110 Received roflumilast cream and had
≥1 safety assessment

107 Received vehicle cream and had
≥1 safety assessment

7 Discontinued participation
in the trial
4 Withdrew
2 Were lost to follow-up
1 Had an adverse event

9 Discontinued participation
in the trial
5 Withdrew
4 Were lost to follow-up

23 Discontinued participation
in the trial
12 Withdrew
5 Were lost to follow-up
2 Did not have efficacy
2 Had an adverse event
1 Was pregnant
1 Had protocol deviation

102 (94%) Completed the trial

104 (92%) Completed the trial

86 (79%) Completed the trial

109 Were included in the intention-to-treat
population

113 Were included in the intention-to-treat
population

109 Were included in the intention-to-treat
population

Figure 1. Randomization and Follow-up of the Patients.
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline (Intention-to-Treat Population).*
Roflumilast Cream, 0.3%
(N = 109)

Characteristic
Age — yr

Roflumilast Cream, 0.15%
(N = 113)

Vehicle Cream
(N = 109)

51.7±14.1

54.4±14.2

55.5±13.5

56 (51)

62 (55)

67 (61)

White

82 (75)

95 (84)

92 (84)

Black

12 (11)

10 (9)

7 (6)

Asian

8 (7)

7 (6)

5 (5)

Male sex — no. (%)
Race — no. (%)†

American Indian or Alaska Native

0

0

1 (1)

7 (6)

1 (1)

4 (4)

6.3±4.0

6.4±3.9

6.4±3.6

2: Mild

17 (16)

18 (16)

11 (10)

3: Moderate

84 (77)

83 (73)

89 (82)

8 (7)

12 (11)

9 (8)

16 (15)

18 (16)

17 (16)

Multiple or other
Percent of body-surface area affected by psoriasis
IGA score — no. (%)‡

4: Severe
Intertriginous area involvement — no. (%)
Intertriginous-area IGA score — no./total no. (%)‡
1: Almost clear

1/16 (6)

2/18 (11)

2: Mild

6/16 (38)

12/18 (67)

3: Moderate

8/16 (50)

3/18 (17)

8/17 (47)

4: Severe

1/16 (6)

1/18 (6)

2/17 (12)

PASI score§

0/17
7/17 (41)

7.7±3.6

8.0±3.9

7.6±3.1

Mean

6.1±2.7

5.6±3.1

5.9±2.9

Score ≥6 — no. (%)

71 (65)

62 (55)

64 (59)

68.9±41.2

69.6±46.2

75.1±42.6

WI-NRS score¶

Psoriasis Symptom Diary total score‖

*	Plus–minus values are ±SD. The intention-to-treat population included all the patients who had undergone randomization. Percentages may
not total 100 because of rounding.
†	Race was reported by the patient.
‡	The Investigator Global Assessment (IGA) is a 5-point scale for assessing plaque thickening, scaling, and erythema; scores range from 0
(clear) and 1 (almost clear) to 4 (severe). Patients in this trial were required to have a score of 2 (mild) or higher.
§	The Psoriasis Area and Severity Index (PASI) is a measurement that combines severity of lesions and the area affected into one score;
scores range from 0 (no disease) to 72 (maximal disease).
¶	The Worst Itch Numeric Rating Scale (WI-NRS) score is a patient-reported assessment of itch in the preceding 24 hours; scores range from
0 (no itch) to 10 (worst itch imaginable).
‖	The Psoriasis Symptom Diary was used to assess variables such as itching, stinging, burning, pain, skin cracking, scaling, and discoloration.
This 16-item scale evaluates the effect of psoriasis symptoms on the patient’s life, with each variable scored on a scale from 0 to 10, with
higher scores indicating greater effect. Overall, the scale of the total score ranges from 0 to 160.

tients who had a reduction of at least 4 points in
the WI-NRS score (a change that was considered
to indicate a response). This was also the case
with regard to the Psoriasis Symptom Diary total score and item scores.

receiving roflumilast 0.15%, and in 30% of those
receiving vehicle (Table 3); 97% of the adverse
events were rated as being mild or moderate in
severity. Four serious adverse events were reported: worsening of chest pain in a patient with
history of myocardial infarction (in the roflumiSafety
last 0.3% group), melanoma (not in the area
Adverse events were reported in 39% of the pa- where roflumilast cream was applied; in the rotients receiving roflumilast 0.3%, in 27% of those flumilast 0.15% group), acute infarction of the
234
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20 (14 to 29)

PASI 90

−42.0 (−48.5 to −35.6)

−44.2 (−50.5 to −37.9)

70 (58 to 80)

13 (8 to 21)

31 (23 to 40)

64 (55 to 73)

−55.0 (−62.8 to −47.2)

49 (24 to 74)

32 (14 to 60)

32 (24 to 41)

27 (20 to 36)

23 (16 to 31)‡

Roflumilast Cream, 0.15%
(N = 113)

−20.9 (−27.3 to −14.5)

33 (22 to 45)

7 (4 to 14)

16 (10 to 24)

24 (17 to 33)

−17.0 (−25.0 to −9.1)

24 (9 to 50)

24 (9 to 50)

16 (10 to 24)

14 (8 to 21)

8 (4 to 15)

Vehicle Cream
(N = 109)

*	All changes and improvements were assessed against baseline values. Missing data were imputed with the use of linear interpolation and the last-observation-carried-forward method
in cases in which linear interpolation was not computationally possible. Unadjusted 95% confidence intervals (CIs) of the point estimates are presented. PSD denotes Psoriasis
Symptom Diary.
†	P<0.001 as compared with vehicle cream.
‡	P = 0.004 as compared with vehicle cream.
§	Secondary outcomes at weeks 2, 4, 6, and 8 are provided in Table S1.
¶	The outcome was assessed in patients with intertriginous-area involvement at baseline (15 patients in the roflumilast 0.3% group, 16 in the roflumilast 0.15% group, and 17 in the
vehicle group).
‖	PASI 50 indicates a reduction from baseline in the PASI score of at least 50%, PASI 75 a reduction of at least 75%, and PASI 90 a reduction of at least 90%. Results of the modified
PASI, from which the PASI score was derived, are shown in Table S2.
**	A WI-NRS response was defined as a reduction of at least 4 points from baseline.

Least-squares mean change in PSD score at wk 12 (95% CI)

63 (51 to 73)

34 (26 to 43)

PASI 75

WI-NRS response at wk 12 among patients with baseline WI-NRS score ≥6 — %
of patients (95% CI)**

62 (53 to 71)

PASI 50

PASI response at wk 12 — % of patients (95% CI)‖

−53.2 (−61.1 to −45.2)

95 (69 to 99)

IGA score of 0 or 1 at wk 12 among patients with baseline intertriginous-area IGA
score ≥2 — % of patients (95% CI)¶

Least-squares mean change in PASI score at wk 12 — % (95% CI)

94 (67 to 99)

38 (29 to 47)

IGA score of 0 or 1 plus 2-grade improvement at wk 12 among patients with baseline intertriginous-area IGA score ≥2 — % of patients (95% CI)¶

31 (23 to 41)

IGA score of 0 or 1 at wk 12 — % of patients (95% CI)

28 (20 to 37)†

Roflumilast Cream, 0.3%
(N = 109)

IGA score of 0 or 1 plus 2-grade improvement at wk 12 — % of patients (95% CI)

Secondary outcomes§

IGA score of 0 or 1 at wk 6 — % of patients (95% CI)

Primary outcome

Outcome

Table 2. Efficacy Outcomes (Intention-to-Treat Population).*
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Table 3. Summary of Adverse Events (Safety Population).*
Roflumilast Cream, 0.3%
(N = 109)

Event

Roflumilast Cream, 0.15%
(N = 110)

Vehicle Cream
(N = 107)

no. of patients with event (%)
42 (39)

30 (27)

32 (30)

Serious adverse event

Any adverse event

1 (1)

1 (1)

2 (2)

Adverse event leading to discontinuation of trial regimen

1 (1)

0

3 (3)

8 (7)

7 (6)

0

Nasopharyngitis

4 (4)

3 (3)

4 (4)

Sinusitis

3 (3)

0

0

Adverse events in >1% of patients in any group
Upper respiratory tract infection

Application-site pain

2 (2)

1 (1)

3 (3)

Limb abscess

2 (2)

0

0

Weight increased

2 (2)

0

0

Pain in arm or leg

2 (2)

0

0

Insomnia

2 (2)

1 (1)

0

Cough

2 (2)

0

0

Hypertension

2 (2)

2 (2)

1 (1)

Viral upper respiratory tract infection

1 (1)

1 (1)

4 (4)

Bronchitis

1 (1)

2 (2)

0

Arthralgia

1 (1)

2 (2)

1 (1)

Influenza-like illness

1 (1)

0

2 (2)

Headache

1 (1)

2 (2)

0

Upper abdominal pain

0

0

2 (2)

Urinary tract infection

0

3 (3)

1 (1)

Contact dermatitis

0

0

2 (2)

7 (6)

3 (3)

7 (7)

Application-site pain

2 (2)

0

3 (3)

Insomnia

2 (2)

0

0

Adverse event considered to be related to the trial regimen
Adverse event considered to be related to the trial regimen
and reported in >1% of the patients in any group

*	The safety population included all the patients who received at least one dose of roflumilast cream or vehicle cream and had at least one
safety assessment.

left basal ganglia (in the vehicle group), and spontaneous miscarriage (in the vehicle group). The
most common adverse events (those occurring
in >3% of the patients in any trial group) were
upper respiratory tract infection, nasopharyngitis, and viral upper respiratory tract infection.
Adverse events that were considered by the
investigators to be related to the intervention were
reported in 6% of the patients receiving roflumilast 0.3%, in 3% of those receiving roflumilast
0.15%, and in 7% of those receiving vehicle. The
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incidence of application-site reactions (in four patients receiving roflumilast 0.3%, in one receiving roflumilast 0.15%, and in five receiving vehicle), gastrointestinal adverse events such as
nausea and diarrhea (in three, two, and three,
respectively), and psychiatric adverse events (in
three, two, and three, respectively) was similar
in the roflumilast groups and the vehicle group.
Three patients in the vehicle group discontinued
the intervention because of an adverse event, as
compared with one patient who received roflu-
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milast 0.3%, who had worsening psoriasis and
discontinued on day 18; no patient who received
roflumilast 0.15% discontinued.
No clinically meaningful differences across
groups were reported for any laboratory variables, electrocardiographs, or vital signs (data
not shown). The incidence of weight loss of
more than 5% of the baseline body weight was
3% among patients receiving roflumilast 0.3%
cream, 4% among those receiving roflumilast
0.15% cream, and 3% among those receiving vehicle cream. The incidence of weight gain of more
than 5% of the baseline body weight was similar
to the incidence of weight loss (Table S3).
No roflumilast-treated patients reported suicidal ideation or behavior, according to the C-SSRS
assessments of suicide risk. Most patients across
the trial groups had no or minimal depression
according to PHQ-8 scores at the start of the
trial (71%) and at the end of the trial (87%), and
there were no differences between the roflumilast groups and the vehicle group.

Discussion
In this 12-week, randomized, double-blind, placebo vehicle–controlled trial, with the primary
outcome assessed at 6 weeks, we found that roflumilast cream was efficacious in reducing the
severity of psoriasis according to an investigator
assessment of a state of clear or almost clear of
plaque psoriasis (IGA score of 0 or 1, respectively). Secondary efficacy assessments, including
those reported by the investigators, were generally in the same direction as that for the primary outcome but, owing to the lack of a plan
for adjustment for multiple comparisons, no
definite conclusions can be drawn from these
data. Improvement was seen by week 2 for both
roflumilast dose levels, as compared with the
vehicle cream, on several scales and with regard
to the Psoriasis Symptom Diary item scores. Outcomes with the higher concentration of roflumilast cream (0.3%) were numerically better than
those with the lower dose (0.15%), but no formal
comparisons were made between dose levels. At
week 8, roflumilast 0.3% resulted in a percentage of patients with improvement on the IGA
scale similar to that reported for topical glucocorticoids on the basis of historical comparisons,
but no conclusions can be drawn because of dif-

n engl j med 383;3

ferences in trial design.19-21 Clinical improvement
was also observed in intertriginous areas.
Given limitations regarding the use of topical
glucocorticoids for the treatment of psoriasis on
the face and intertriginous areas, because of
thinner skin in these locations and a chance of
systemic absorption, we used an intertriginousarea IGA scale to assess the population of patients with this condition separately from patients
who had lesions only on nonintertriginous sites.
Among patients with at least mild intertriginous
psoriasis at baseline who were treated with roflumilast 0.3%, treatment success (score of 0 or
1 plus a 2-grade improvement) was observed in
nearly half the patients by week 4, in nearly three
quarters of the patients by week 6, and in almost
90% of the patients by week 8, with nearly all the
patients having an intertriginous-area IGA score
of 0 (indicating a clear status).22
The oral PDE-4 inhibitor apremilast has been
used for the treatment of moderate-to-severe
plaque psoriasis.10 In previous trials, approximately
30% of the patients with moderate-to-severe
plaque psoriasis (body-surface area involvement
of ≥10% and PASI score of ≥12) who were taking
apremilast met the criterion for PASI 75 at week
16.10,23 In the current phase 2b trial, in which
approximately 85% of the enrolled patients had
moderate-to-severe disease, a generally similar
percentage of patients in the roflumilast 0.3%
group (31%) met the criterion for the PASI 75 response at week 8, but differences in trial design
do not allow direct comparisons to be made.
Apremilast has been associated with gastrointestinal adverse events of diarrhea and nausea,
whereas topical administration of roflumilast
cream was associated with an incidence of less
than 1% of each of these events in the present
trial, possibly as a result of bypassing the gastrointestinal tract with topical administration. Another PDE-4 inhibitor, crisaborole, has been approved in an ointment formulation for the
treatment of atopic dermatitis and has also been
used to treat psoriasis. Local irritation is the
main reported adverse event. In our trial of roflumilast cream, application-site reactions were
similar in the active-treatment groups and in the
vehicle group.
Limitations of the trial include the short duration of 12 weeks, the duration of only 6 weeks
for assessing the primary outcome in patients
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with this chronic disease, and the small sample
of patients with intertriginous psoriasis (approximately 15% of the patients). We were also unable
to draw clinical conclusions regarding the large
number of secondary outcomes as a result of the
lack of a plan for adjustment of the 95% confidence intervals for multiple comparisons.
This phase 2b trial of roflumilast cream
showed greater reductions in psoriasis signs and
symptoms than placebo vehicle cream at 6 weeks.
Longer and larger trials are necessary to determine the effectiveness and safety of roflumilast.
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